Skip to main content

Table 1 Clinical features and EYA2 protein expression in patients with HCC (n = 94)

From: EYA2 suppresses the progression of hepatocellular carcinoma via SOCS3-mediated blockade of JAK/STAT signaling

Clinicopathological EYA2 protein expression P value
variables High (n = 44, 46.81%) Low (n = 50, 53.19%)
Age (years)
  ≥ 50 31 (32.98%) 27 (28.72%) 0.102
  < 50 13 (13.83%) 23 (24.47%)  
Gender
 Male 39 (41.49%) 43 (45.74%) 0.702
 Female 5 (5.32%) 7 (7.45%)  
Tumor number
 single 32 (34.04%) 37 (39.36%) 0.889
 multiple 12 (12.77%) 13 (13.83%)  
Tumor size (cm)
  < 5 24 (25.53%) 11 (11.70%) 0.001
  ≥ 5 20 (21.28%) 39 (41.49%)  
Liver cirrhosis
 Yes 31 (32.98%) 30 (31.91%) 0.289
 No 13 (13.83%) 20 (21.28%)  
Serum AFP (ng/ml)
  ≤ 20 19 (20.21%) 14 (14.89%) 0.124
  > 20 25 (26.60%) 36 (38.30%)  
HBsAg
 Positive 41 (43.62%) 43 (45.74%) 0.429
 Negative 3 (3.19%) 7 (7.45%)  
BCLC stage
 0–A 23 (24.47%) 14 (14.89%) 0.016
 B–C 21 (22.34%) 36 (38.30%)  
TNM stage
 I 30 (31.91%) 28 (29.79%) 0.225
 II–IV 14 (14.89%) 22 (23.40%)  
Tumor differentiation
 I–II 21 (22.34%) 14 (14.89%) 0.048
 III–IV 23 (24.47%) 36 (38.30%)  
  1. Chi-square test was performed for statistical analysis. P < 0.05 was considered statistically significant. AFP α-fetoprotein, HBsAg hepatitis B surface antigen, BCLC Barcelona Clinic Liver Cancer, TNM tumor node metastasis